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Type II Diabetes and its Treatment
Gregory Mountain RN, BSN,CCRN
Otterbein University, Westerville, Ohio

Signs and Symptoms. Complications Cont’d
1) Polyuria (McCulloch, Nathan,
Wolfsdorf, & Mulder, 2015)
2) Polydipsia (McCulloch, et al., 2015)
3) Elevated glycated hemoglobin A1C
A. A1C greater than 6.1% (McCulloch,
et al. , 2015)
4) Increased BMI (McCulloch, et
al.,2015)
5) Increased fasting glucose (McCulloch,
et al.,2015)
6) Glycosuria (McCulloch, et al.,2015)
7) Acute changes in vision (McCulloch, et
al.,2015)

Complications
1) Diabetic Retinopathy-Diabetes is one
of the major causes of blindness (CDC,
1991).Chronic hyperglycemia causes
increased capillary permeability and the
capillaries become less functional (CDC,
1991). Due the this fact, microaneurysms
form, retinal capillaries close, a formation
of fibrous tissue and new vesselsare
created, hemorrhages and/or retinal
detachment are all signs of diabetic
retinopathy (CDC, 1991).
A. Glaucoma, cataracts and macular
edema are complications resulting
from poorly managed DM2
2) Diabetic Nephropathy-DM2’s effect on
the kidney is still widely unknown (CDC,
1991). Hyperglycemia and hypertension
contribute to diabetic glomerulosclerosis,
increased thickening of the glomerular
basement membrane and mesangial
expansion (CDC, 1991). Increased blood
flow to the kidney from hyperglycemia
cause an increased size and weight of the
kidney (CDC,1991). Microalbuminuria (30
to 300 mg/day)is usually one of the first
notable signs of kidney disease
(CDC,1991).
3) Cardiovascular disease-patients with
DM2 are 2 to 3 times more likely to have
cardiovascular disease (CDC, 1991).
Coronary artery disease and stroke are
common complications as a result from
chronic hyperglycemia. Atherosclerosis
contributing to these complications is
caused from abnormal platelet function,
hyperinsulinemia, impaired blood flow
and coagulopathies (CDC, 1991)
Cardiovascular disease is the leading
cause of death for patients with DM2
(CDC, 1991).
4) Diabetic Neuropathy-The three types
are distal symmetrical polyneuropathy,
focal neuropathy, and autonomic
neuropathy. They result from poorly
controlled blood sugar and decreased
blood flow to the nerves (CDC, 1991).

Distal symmetrical neuropathy is
characterized by dysesthesia and
paresthesia in the lower extremities (CDC,
1991). As the neuropathy progresses with
poor glycemic control, varying degrees and
pain and sensation loss occur (CDC, 1991).
Focal neuropathy is an uncommon form
associated a blood vessel occlusion.
Symptoms are usually unsymmetrical in
nature and have a sudden, acute onset
(CDC, 1991). Autonomic neuropathy
affects multiple body systems. The
symptoms include: orthostatic
hypotension, gastroparesis, constipation,
diarrhea, fecal incontinence, bladder
dysfunction and sexual dysfunction such
as impotence and dyspareunia (CDC,
1991).
1)Lower extremity ulcers and
amputations-they are a result of diabetic
neuropathy and cardiovascular disease
caused by DM2 (CDC, 1991). Due to the
loss of sensation deformities can occur
which lead to ulcerations (CDC, 1991).
The ulcers are slow to heal due to the
poor blood flow from peripheral artery
disease (CDC, 1991). Unhealed ulcers
become infected leading to gangrene and
osteomyelitis (CDC, !991). These
conditions often require amputation of
part or all of the affect area (CDC, 1991).
50% of the nontraumatic amputations in
the United States are a result of diabetes
(CDC, 1991).

Dietary and Exercise
Recommendations
Cont’d
1) Carbohydrates-50% of a patients caloric
intake should consist of carbohydrates; but of
that, less that 10% should be made up of
sugars (Bussell, 2014).
2) Sugar-it is recommended that less than 90g
of sugar be consumed per day. However,
these sugars should be naturally found in food
such as honey, fruit, and milk (Bussell, 2014).
3) Fats-total fat intake should not exceed 70g
per day. Mono-unsaturated fats are
recommended such as oily fish, peanuts,
avocado, olive oil etc. (Bussell, 2014).
4) Fiber- 24g per day are recommended. Soluble
fiber has been shown to reduce cholesterol
and improve blood sugar control (Bussell,
2014).
5) Proteins-should make up 25% of a patients
caloric intake. It helps increase the feeling of
satiety allowing the patient to go longer
periods without feeling hungry (Bussell, 2014).

Nursing Implications

Education, preventative care, symptom recognition
and appropriate treatment are imperative for
patients at risk and/or patients with type II
diabetes (CDC, 1991). Nurses are the front line
when it comes helping patient manage DM2. They
must educate patients on everything from proper
diet and exercise to when and how to take their
medications (CDC, 1991). Nurses must be
knowledgeable on preventative care to help
patients monitor and avoid the many complications
associated with DM2 (CDC, 1991). Education on
Weight reduction through dietary
blood sugar management and if the prescribed
modification can help improve glycemic
treatment is properly controlling the patient’s
control by decreasing insulin resistance and blood sugar is largely on the nurses shoulders
increase insulin secretion (McCulloch,
(CDC, 1991). Most importantly, nurses must
Nathan, & Mulder, 2015). 30-60 minutes of recognize the signs and symptoms of uncontrolled
moderate intensity aerobic activity is
diabetes in an undiagnosed patient (CDC, 1991).
recommended most days of the week
(McCulloch, Nathan, & Mulder, 2015).
Graphic retrieved from
Weight lifting should be done at least twice
www.salemfreemedclinic.org
per week (McCulloch, Nathan, & Mulder,
2015

Dietary and Exercise
Recommendations

Introduction
Approximately 28.9 million
Americans have been diagnosed
with type II diabetes (Jia-Haur Hu,
Lin, Miller, Nguyen, & Nguyen,
2014). It is a disease that can cause
or potentiate numerous
comorbidities that negatively
affects multiple body systems if left
untreated (Jia-Haur Hu, et al.,
2014). In 2012, the total estimated
cost for treatment of type II
diabetes in America was an
astronomical $245 billion (Jia-Haur
Hu, et al., 2014).

1)

Type II diabetes is a result of many
cellular processes that lead to insulin
resistance resulting in increased blood
glucose levels (Jia-Haur Hu, et al.,
2014). Treatments for type II diabetes
include several different classifications
of oral hypoglycemic medications,
insulin injections, exercise, and a
modified diet (Jia-Haur Hu, et al.,
2014). With the number of Americans
being diagnosed with type II diabetes 2)
on the rise, a strong understanding of
the pathophysiology of the disease and
its treatments cannot be disregarded.

Pathogenesis
Type II diabetes (DM2) can result from
genetic and environmental influences or
both. Making it difficult to determine the
specific cause in each patient (McCulloch,
Robertson, Nathan, & Mulder, 2014).
However, DM2 is characterized by
hyperglycemia, insulin resistance, and
relative impairment in insulin secretion
(McCulluch, et al., 2014). Hyperglycemia
can impair pancreatic beta cell function
thus perpetuating the body’s insulin
resistence leading to an even worse
metabolic state (McCulluch, et al., 2014).
Insulin secretion helps move glucose into
the cell, which is mediated by glucose
transporter 2 (GLUT-2) (McCulluch, et al.,
2014). The alteration of GLUT-2 can be
linked to a high- fat diet in a mouse model
decreasing insulin secretion in those mice
(McCulluch, et al., 2014). A large majority
of DM2 patients have shown to have
genetic susceptibility to insulin resistance
(McCulluch, et al., 2014). This fact could be
attributed to idea that insulin resistance
becomes worse with increasing age and
body weight (McCulluch, et al., 2014).
Individuals with the genetic predisposition
for DM2 so signs of increased insulin
resistance causing hyperglycemia. In a
cyclic manner, that hyperglycemia
contributes to future weight gain in those
patients (McCulluch, et al., 2014). Adipose
tissue releases leptin, adiponectin, Tumor
necrosis factor alpha, and resistin, which
relate to increasing insulin resistance
(McCulluch, et al., 2014).

The dysregulation of fatty acid metabolism
and decreased glycogen synthesis can be an
inherited defect than contributes to insulin
resistance (McCulluch, et al., 2014). The
process of converting proinsulin to insulin is
shown to be impaired in the beta cells of DM2 3)
patients. Increased amounts of proinsulin are
still produced in DM2 to account for
increasing demands but are not able to be
converted into insulin due to this beta cell
dysfunction (McCulluch, et al., 2014). Amylin
is secreted along with insulin in the pancreatic
beta cells. Increased amounts of amylin
reduce glucose uptake and inhibit insulin
secretion (McCulluch, et al., 2014). Amylin
concentrations are found to be extremely low
in patients with DM2 patients (McCulluch, et
al., 2014). Other genetic factors for DM2
4)
include ethnicity and having familial history of
DM2. African americans are up to six times
more likely to have DM2 (McCulluch, et al.,
2014). Having a first-degree relative can make
a patient up to ten times more susceptible to
DM2 (McCulluch, et al., 2014). Maturity onset
of diabetes of the young or MODY is an
autosomal dominate form of insulin resistance
and impaired insulin secretion from a
mutation on chromosome 7 effecting
glucokinase genes (McCulluch, et al., 2014).
Inflammation markers such as C reactive
protein, IL-6, plasminogen activator inhibitor1, tumor necrosis factor alpha, and white cell 5)
count can all be linked between obesity and
DM2, which correlates to insulin resistance
(McCulluch, et al., 2014).

Treatments

Metformin-is the most widely used
oral DM2 medication on the market. It
decreases hepatic insulin production,
decreases reabsorption of intestinal
glucose and decreases insulin
resistance (McCulluch, Nathan,
Mulder, 2014). Metformin can be used
in conjunction with other DM2
medications or insulin therapy.
Combination therapy with DPP-4 has
shown to decrease patient’s HgA1c
more than just treatment with
Metformin alone (Liu & Wu, 2014).
DDP-4 inhibitors-The inhibit the
enzyme GLP-1, which decreases
fasting plasma glucose, post prandial
glucose, and HbA1C. The common side
effects for this class is nausea,
headache, renal and hepatic
dysfunction (Eyadeh, & Jennings,
2015)
A. This class consists of Sitagliptin,
Saxagliptin, Linagliptin, Alogliptin
and Vildagliptin (Eyadeh, &
Jennings, 2015).
SGLT inhibitors- they inhibit renal
absorption of glucose so that in is
dumped in the urine (Eyadeh, &
Jennings, 2015). The SGLT inhibitors
contribute to lower blood pressure,
weight loss, decreased lipids and
decreased uric acid (Eyadeh, &
Jennings, 2015).
A. This class consists of
Dapagliflozin, Canagliflozin,
Empagliflozin (Eyadeh, &
Jennings, 2015).
GLP-1 agonists-incretion secreted
from the intestinal mucosa, which is
released into circulation with the
ingestion of food (Eyadeh, & Jennings,
2015). GLP-1 agonist mimic incretion
thus stimulation the secretion of
insulin (Eyadeh, & Jennings, 2015).
Nausea is the main side effect for this
class medication (Eyadeh, & Jennings,
2015).
A. This class consists of Exenatide,
Liraglutide, Lixisenatide, and
Albiglutide (Eyadeh, & Jennings,
2015).
Alpha glucosidase inhibitors-slow the
absorption of intestinal glucose
causing a slower rise in postprandial
blood sugars (McCulluch, Nathan,
Mulder, 2014). However, they are
usually poorly tolerated due to their GI
side effects (McCulluch, Nathan,
Mulder, 2014).

6)

Insulin- It is usually added when oral
agents become less effective and lifestyle
changes are no longer appropriately
controlling blood sugar. It can be added
as an adjunct to oral medication or used
as primary therapy. Disadvantages for
the use of insulin therapy include weight
gain and hypoglycemia (McCulloch,
Nathan, Mulder, 2015)
A. Basal insulin- intermediate to long
acting insulin such as NPH, NPL,
glargine, or detemir. It is given once or
twice a day to suppress hepatic
glucose production in a fasting state.
(McCulloch, Nathan, Mulder, 2015).
i. Onset-2 hours
ii. Peak
a. NPH (4-12 hours)
b. NPL (6 hours)
c. Glargine (no peak)
d. Detemir (3-9 hours)
iii. Duration
a. NPH (18-28 hours)
b. NPL (15 hours)
c. Glargine (20-greater than 24
hours)
d. Detemir (6-24 hours)
B. Prandial dose insulin- short acting or
rapid acting insulin such as regular,
lispro, aspart, and glulisine given after
meals to counteract food absorption
(McCulloch, Nathan, Mulder, 2015).
i. Onset
a. Regular (30 minutes)
b. Lispro, apart and glulisine (515 minutes)
ii. Peak
a. Regular (2-4 hours)
b. Lispro, apart and glulisine
(45-75 minutes)
iii. Duration
a. Regular (5-8 Hours)
b. Lispro, apart and glulisine (24)
C. Afrezza-is a recombinant
regular human insulin
inhalation powder (Jia-Haur
Hu, et al., 2014). It is market
as the alternative to
injectable short acting
insulin therapy (Jia-Haur Hu,
et al., 2014).
7)
Bariatric surgery-this is not a primary
treatment for DM2 but helps treat an
underlying cause of DM2. The
reduction of weight is associated with
a decrease in insulin resistance. More
than 50% of the patients who undergo
bariatric surgery decrease their HgA1c
within normal limits without
medication (Wilding, 2015)
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